Manikandan Dhanushkodi

Manikandan Dhanushkodi

Auto-generated profile, based on publicly available information

Manikandan Dhanushkodi

Department of Medical Oncology, Cancer Institute (WIA), Chennai, Tamil Nadu, India

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2021 in JCO Global Oncology
Verified
Journal Article
Open access
MDManikandan Dhanushkodi
Manikandan Dhanushkodi
VSVelusamy Sridevi
Velusamy Sridevi
VSViswanathan Shanta
Viswanathan Shanta
RRRanganathan Rama
Ranganathan Rama
RSRajaraman Swaminathan
Rajaraman Swaminathan
TGTrivadi S. Ganesan
Trivadi S. Ganesan
PURPOSE: There are sparse data on the outcome of patients with locally advanced breast cancer (LABC). This report is on the prognostic factors and long-term outcome from Cancer Institute, Chennai.METHODS: This is an analysis of untreated patients with LABC (stages IIIA-C) who were treated from January 2006 to December 2013.RESULTS: Of the 4,577 patients with breast cancer who were treated, 2,137 patients (47%) with LABC were included for analysis. The median follow-up was 75 months (range, 1-170 months), and 2.3% (n = 49) were lost to follow-up at 5 years. The initial treatment was neoadjuvant concurrent chemoradiation (NACR) (77%), neoadjuvant chemotherapy (15%), or others (8%). Patients with triple-negative breast cancer had a pathologic complete response (PCR) of 41%. The 10-year overall survival was for stage IIIA (65.1%), stage IIIB (41.2%), and stage IIIC (26.7%). Recurrence of cancer was observed in 27% of patients (local 13% and distant 87%). Multivariate analysis showed that patients with a tumor size > 10 cm (hazard ratio [HR], 2.19; 95% CI, 1.62 to 2.98; P = .001), hormone receptor negativity (HR, 1.45; 95% CI, 1.22 to 1.72; P = .001), treatment modality (neoadjuvant chemotherapy, HR, 0.56; 95% CI, 0.43 to 0.73; P = .001), lack of PCR (HR, 2.36; 95% CI, 1.85 to 3.02; P = .001), and the presence of lymphovascular invasion (HR, 1.97; 95% CI, 1.60 to 2.44; P = .001) had decreased overall survival.CONCLUSION: NACR was feasible in inoperable LABC and gave satisfactory long-term survival. PCR was significantly higher in patients with triple-negative breast cancer. The tumor size > 10 cm was significantly associated with inferior survival. However, this report acknowledges the limitations inherent in experience of management of LABC from a single center.

13 October 2020 in ecancermedicalscience
Verified
Journal Article
Open access
SMSharada Mailankody
Sharada Mailankody
MDManikandan Dhanushkodi
Manikandan Dhanushkodi
TGTrivadi S Ganesan
Trivadi S Ganesan
VRVenkatraman Radhakrishnan
Venkatraman Radhakrishnan
VCVasanth Christopher
Vasanth Christopher
TSTenali Gnana Sagar
Tenali Gnana Sagar
Recurrent cervical cancer treated with palliative chemotherapy: real-world outcome Sharada Mailankody1,2a, Manikandan Dhanushkodi1b, Trivadi S Gane

1 February 2019 in Clinical Lymphoma Myeloma and Leukemia
Verified
Journal Article
Closed access
PGPrasanth Ganesan
Prasanth Ganesan
MDManikandan Dhanushkodi
Manikandan Dhanushkodi
TGTrivadi S. Ganesan
Trivadi S. Ganesan
VRVenkatraman Radhakrishnan
Venkatraman Radhakrishnan
KKKrishnarathinam Kannan
Krishnarathinam Kannan
TSTenali Gnana Sagar
Tenali Gnana Sagar

1 March 2018 in Pediatric Hematology Oncology Journal
Verified
Journal Article
Open access
AMAvaronnan Manuprasad
Avaronnan Manuprasad
VRVenkatraman Radhakrishnan
Venkatraman Radhakrishnan
SJSunil B. J
Sunil B. J
ARA.S. Ramakrishnan
A.S. Ramakrishnan
TGT.S. Ganesan
T.S. Ganesan
TST.G. Sagar
T.G. Sagar

2 August 2022 in Indian Journal of Cancer
Verified
Journal Article
Open access
SMSharada Mailankody
Sharada Mailankody
VRVenkatraman Radhakrishnan
Venkatraman Radhakrishnan
ARAnand Raja
Anand Raja
TGTrivadi S. Ganesan
Trivadi S. Ganesan
MDManikandan Dhanushkodi
Manikandan Dhanushkodi
TSTenali Gnana Sagar
Tenali Gnana Sagar
Background: Carcinoma penis is more common in India compared to the West. The role of chemotherapy in carcinoma penis is ambiguous. We analyzed the profile and outcomes of patients with carcinoma penis treated with chemotherapy. Methods: We analyzed the details of all patients with carcinoma penis treated at our institute between 2012 and 2015. We collected particulars regarding demography, clinical presentation, treatment details, toxicities, and outcomes of these patients. Event-free and overall (OS) survival were calculated from the time of diagnosis until documentation of disease relapse/progression or death for the patients with advanced carcinoma penis who were eligible for chemotherapy. Results: There were 171 patients with carcinoma penis treated at our institute during the study period including 54 (31.6%) patients with stage I, 49 (28.7%) patients with stage II, 24 (14.0%) patients with stage III, 25 (14.6%) patients with stage IV, and 19 (11.1%) patients with recurrent disease at presentation. The present study included 68 patients with advanced carcinoma penis (stages III and IV) who were eligible for chemotherapy, with a median age of 55 years (range: 27–79 years). Sixteen patients received paclitaxel and carboplatin (PC) and 26 patients cisplatin and 5-FluoroUracil (CF). Neoadjuvant chemotherapy (NACT) was given to four patients with stage III and nine patients with stage IV disease. Of the 13 patients given NACT, we observed a partial response in five (38.5%), stable disease in two (15.4%), and progressive disease in five (38.5%) evaluable patients. Six (46%) patients underwent surgery after NACT. Only 28/54 (52%) patients received adjuvant chemotherapy. After a median follow-up of 17.2 months, the 2-year OS rates were 95.8, 89, 62.7, 51.9, and 28.6% for stages I, II, III, IV, and recurrent disease, respectively. The 2-year OS of patients who were given chemotherapy versus those who were not given chemotherapy were 52.7 and 63.2%, respectively (P = 0.762). Conclusions: We report the real-world outcomes of two chemotherapeutic regimens used in consecutive patients with advanced carcinoma penis. Both PC and CF seemed effective and safe. However, approximately half of patients with advanced carcinoma penis do not receive the planned/indicated chemotherapy. We need further prospective trials regarding the sequencing, protocols and indications of chemotherapy in this malignancy.

1 March 2020 in Indian Journal of Medical and Paediatric Oncology
Verified
Journal Article
Open access
PDF file
VGVijay Gnanaguru
Vijay Gnanaguru
MDManikandan Dhanushkodi
Manikandan Dhanushkodi
VRVenkatraman Radhakrishnan
Venkatraman Radhakrishnan
JKJayachandran Perumal Kalaiarasi
Jayachandran Perumal Kalaiarasi
NMNikita Mehra
Nikita Mehra
TSTenali Gnana Sagar
Tenali Gnana Sagar
Background: Cyclin-dependent kinase 4/6 inhibitor addition to hormonal therapy has shown to improve the survival of hormone receptor (HR)-positive, HER2-negative advanced breast cancer (ABC). Methods: We retrospectively analyzed untreated patients with HR-positive, HER2-negative ABC, who received letrozole and palbociclib at the Cancer Institute, Chennai, from October 2017 to January 2019. Results: A total of 24 patients were included in this study. The median progression-free survival (PFS) was 18 months, and the median overall survival (OS) had not reached. The 1-year PFS and OS were 73.7% and 89.2%, respectively. The common toxicities were neutropenia and fatigue but none of the patients had febrile neutropenia. Conclusion: Letrozole-Palbociclib is effective with manageable toxicity as the first-line treatment for HR-positive, HER2-negative ABC. Received: 22 July 2019 Accepted: 02 January 2020 Publication Date: 23 May 2021 (online) © 2020. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.) Thieme Medical and Scientific Publishers Pvt. Ltd. A-12, 2nd Floor, Sector 2, Noida-201301 UP, India